



# Marksans Pharma Ltd.

Date: 20<sup>th</sup> January, 2023

**BSE Limited**  
Corporate Relation Department  
PhirozeJeejeeboi Towers,  
Dalal Street,  
Mumbai - 400001.  
Scrip Code: 524404

**National Stock Exchange of India Limited**  
Listing Department  
Exchange Plaza, C-1, Block-G,  
Bandra-Kurla Complex,  
Bandra (East), Mumbai - 400051.  
Symbol: MARKSANS

Dear Sir,

Re: Outcome of Board Meeting

This is to inform you that the Board of Directors at its meeting held today, i.e., 20<sup>th</sup> January, 2023, has created, issued and allotted fully paid-up Equity Shares having face value of Re. 1/- each on conversion of convertible warrants issued on preferential basis as per details below:

- (a) 10,00,000 fully paid-up Equity Shares of the face value of Re. 1/- each to Mr. Mark Saldanha (Promoter of the Company) at a price of INR 74.00 per Equity Share, being the price not less than the price determined in accordance with Chapter V of SEBI (ICDR) Regulations, 2018; and
- (b) 4,93,24,324 fully paid-up Equity Shares of the face value of Re. 1/- each to OrbiMed Asia IV Mauritius FVCI Limited at a price of INR 74.00 per Equity Share, being the price not less than the price determined in accordance with Chapter V of SEBI (ICDR) Regulations, 2018.

The above allottees had intimated the Company exercising their rights to convert the convertible warrants into Equity Shares and have paid the full subscription money for issue and allotment of Equity Shares.

The Equity Shares allotted as above shall rank pari-passu in all respect including with respect to dividend with the existing Equity Shares of the Company.

Accordingly, the Issued, Subscribed and Paid-up Equity Share Capital of the Company has increased to Rs. 45,31,63,746.00 (Rupees Forty-Five Crore Thirty-One Lakh Sixty-Three Thousand Seven Hundred Forty Six only) divided into 45,31,63,746 (Forty Five-Crore Thirty One Lakh Sixty-Three Thousand Seven Hundred Forty Six only) Equity Shares of face value of Re. 1/- (Rupee One only) each with effect from 20<sup>th</sup> January, 2023.

The details as required under SEBI (LODR) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 with respect to the preferential issue are given in **Annexure – A**.

The meeting of the Board of Directors commenced at 09:00 AM and concluded at 09:40 AM.

You are requested to note the above in your records.

[www.marksanspharma.com](http://www.marksanspharma.com)

## Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,  
Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • Fax : +91-22 4001 2011  
E-mail: [info@marksanspharma.com](mailto:info@marksanspharma.com)



# Marksans Pharma Ltd.

For Marksans Pharma Limited

Thanking You,

Enclosed as above

Harshavardhan Panigrahi  
Company Secretary

## Annexure - A Conversion of Warrants and Allotment of Equity Shares

Sr. No.	Particulars	Details
1	Type of securities issued (viz. Equity shares, convertibles etc.)	Fully paid-up Equity Shares of Re. 1/- each face value issued upon exercise of conversion of Convertible Warrants.
2	Type of issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment etc.)	Fully paid-up Equity Shares of Re. 1/- each face value issued upon exercise of conversion of Convertible Warrants which were issued by way of Preferential Issue in accordance with Chapter V of SEBI (ICDR) Regulations, 2018.
3	Total number of securities issued or the total amount for which the securities issued (approximately)	(a) 10,00,000 fully paid-up Equity Shares of face value of Re 1/- each per Equity Share against 10,00,000 convertible warrants. (b) 4,93,24,324 fully paid-up Equity Shares of face value of Re 1/- each per Equity Share against 4,93,24,324 convertible warrants.
	<b>Additional details in case of preferential issue</b>	
4	Name of investors	(a) Mr. Mark Saldanha (Promoter) (10,00,000 Equity Shares) (b) OrbiMed Asia IV Mauritius FVCI Limited (4,93,24,324 Equity Shares)
5	Number of Investors	2
6	Post allotment of securities- outcome of the subscription:	(a) Issue price of each Equity Share: Rs 74 (including premium of Rs. 73) (b) Conversion ratio of each Warrants into Equity Shares: 1:1.
7	In case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument	Exercise of 5,03,24,324 convertible warrants into 5,03,24,324 Equity Shares of the face value of Re. 1/- each.

CIN : L24110MH1992PLC066364

[www.marksanspharma.com](http://www.marksanspharma.com)

### Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • Fax : +91-22 4001 2011  
E-mail: [info@marksanspharma.com](mailto:info@marksanspharma.com)